Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock
Analysts raised their price targets on RARE stock after the FDA granted accelerated regulatory approval for its rare metabolic disease therapy. Wells Fargo lifted the stock’s price target to $46 and kept an ‘Overweight’ rating, according to The Fly. Ultragenyx also received a priority review voucher from the FDA, which will allow it to request … Read more